Inhalation of Mesenchymal Stem Cell- Derived Small Extracellular Vesicles as a Possible Approach to Ameliorating Acute Lung Injury Caused by Cytokine Storm
Student Research in Translational Medicine,
Vol. 6 (2024),
24 January 2024
https://doi.org/10.22037/srtm.v6.44112
Abstract
Lung is one of the vital organs that get severely affected by cytokine storm and sepsis, leading to the development of acute lung injury (ALI) or acute respiratory distress syndrome (ARDS). Mesenchymal stem cell- derived small extracellular vesicles (MSC- derived sEVs) are one of the therapeutic approaches for ARDS/ ALI caused by sepsis. Apart from sEVs’ ability to carry medication, MSC- derived sEVs also possess anti- inflammatory, tissue repair, and regeneration properties. Targeted drug delivery has been a crucial area of concern in the medical field, specifically for treating lung diseases. To treat lung diseases locally, inhalation of drug products has been developed. Drug delivery by inhalation has emerged as an effective method for local administration of therapeutic agents, with numerous benefits including better efficacy at lower doses and decreased toxicity. Additionally, inhalation administration is a viable option for the systemic distribution of medications due to the lungs' considerable absorption surface and their ability to bypass initial metabolism. Therefore, our hypothesis proposes the inhalation of MSC- derived sEVs as a potential strategy for alleviating acute lung injury induced by sepsis-related cytokine storm. Following the isolation and characterization of these MSC- derived sEVs, they will be administered to an animal model of sepsis via a nebulizer, either in their pure form or loaded with drugs. Several approaches will be employed to evaluate lung functionality, including histological analysis and the measurement of inflammatory and regulatory cytokine levels to assess changes in both the humoral and cellular immune systems.
- Sepsis
- Small extracellular vesicles
- Inhalation
- Acute lung injury
- Mesenchymal stem cells.
How to Cite
References
Fajgenbaum DC, June CHJNEJoM. Cytokine storm. 2020;383(23):2255-73.
Sun X, Wang T, Cai D, Hu Z, Liao H, Zhi L, et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia. 2020;53:38-42.
Hu B, Huang S, Yin LJJomv. The cytokine storm and COVID‐19. 2021;93(1):250-6.
Fleischmann C, Scherag A, Adhikari NK, Hartog CS, Tsaganos T, Schlattmann P, et al. Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. 2016;193(3):259-72.
Czermak BJ, Breckwoldt M, Ravage ZB, Huber-Lang M, Schmal H, Bless NM, et al. Mechanisms of enhanced lung injury during sepsis. 1999;154(1):1057-65.
Li W, Li D, Chen Y, Abudou H, Wang H, Cai J, et al. Classic signaling pathways in alveolar injury and repair involved in sepsis-induced ALI/ARDS: New research progress and prospect. 2022;2022.
Root-Bernstein RJIjoms. Innate receptor activation patterns involving TLR and NLR synergisms in COVID-19, ALI/ARDS and sepsis cytokine storms: a review and model making novel predictions and therapeutic suggestions. 2021;22(1):2108.
Moriyama K, Nishida OJIjoms. Targeting cytokines, pathogen-associated molecular patterns, and damage-associated molecular patterns in sepsis via blood purification. 2021;22(16):8882.
Denning N-L, Aziz M, Gurien SD, Wang PJFii. DAMPs and NETs in sepsis. 2019;10:2536.
Nofi CP, Wang P, Aziz MJCD, Disease. Chromatin-Associated Molecular Patterns (CAMPs) in sepsis. 2022;13(8):1-15.
Chen AX, Simpson SQ, Pallin DJJNEJM. Sepsis guidelines. 2019;380(14):1369-71.
Mei SH, Haitsma JJ, Dos Santos CC, Deng Y, Lai PF, Slutsky AS, et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. 2010;182(8):1047-57.
Ho MS, Mei SH, Stewart DJJJocp. The immunomodulatory and therapeutic effects of mesenchymal stromal cells for acute lung injury and sepsis. 2015;230(11):2606-17.
Chang C-L, Sung P-H, Chen K-H, Shao P-L, Yang C-C, Cheng B-C, et al. Adipose-derived mesenchymal stem cell-derived exosomes alleviate overwhelming systemic inflammatory reaction and organ damage and improve outcome in rat sepsis syndrome. 2018;10(1):1053.
Sun J, Sun X, Chen J, Liao X, He Y, Wang J, et al. microRNA-27b shuttled by mesenchymal stem cell-derived exosomes prevents sepsis by targeting JMJD3 and downregulating NF-κB signaling pathway. 2021;12(1):1-15.
Lee Y-H, Park H-K, Auh Q-S, Nah H, Lee JS, Moon H-J, et al. Emerging potential of exosomes in regenerative medicine for temporomandibular joint osteoarthritis. 2020;21(1):1541.
Song Y, Dou H, Li X, Zhao X, Li Y, Liu D, et al. Exosomal miR-146a contributes to the enhanced therapeutic efficacy of interleukin-1β-primed mesenchymal stem cells against sepsis. 2017;35(5):1208-21.
Qiu P, Zhou J, Zhang J, Dong Y, Liu YJFiP. Exosome: the regulator of the immune system in sepsis. 2021;12:671164.
Wu J, Wang Y, Li LJBeBA-MBoD. Functional significance of exosomes applied in sepsis: a novel approach to therapy. 2017;1863(1):292-7.
Choi H, Kim Y, Mirzaaghasi A, Heo J, Kim YN, Shin JH, et al. Exosome-based delivery of super-repressor IκBα relieves sepsis-associated organ damage and mortality. 2020;6(15):eaaz6980.
Park EJ, Appiah MG, Myint PK, Gaowa A, Kawamoto E, Shimaoka MJCpd. Exosomes in sepsis and inflammatory tissue injury. 2019;25(42):4486-95.
Monsel A, Zhu Y-g, Gennai S, Hao Q, Hu S, Rouby J-J, et al. Therapeutic effects of human mesenchymal stem cell–derived microvesicles in severe pneumonia in mice. 2015;192(3):324-36.
Song Y, Kim Y, Ha S, Sheller‐Miller S, Yoo J, Choi C, et al. The emerging role of exosomes as novel therapeutics: Biology, technologies, clinical applications, and the next. 2021;85(2):e13329.
Rau JLJRc. The inhalation of drugs: advantages and problems. 2005;50(3):367-82.
Forest V, Pourchez J. Nano-delivery to the lung-by inhalation or other routes and why nano when micro is largely sufficient?. Advanced Drug Delivery Reviews. 2022 Apr 1;183:114173.
Al-Khawaga S, Abdelalim EMJSCR, Therapy. Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients. 2020;11(1):1-33.
Abbaszadeh H, Ghorbani F, Abbaspour-Aghdam S, Kamrani A, Valizadeh H, Nadiri M, et al. Chronic obstructive pulmonary disease and asthma: mesenchymal stem cells and their extracellular vesicles as potential therapeutic tools. 2022;13(1):1-15.
- Abstract Viewed: 176 times
- PDF Downloaded: 97 times
